$1,318.00
Thyroid eye disease (TED), also called Graves’ ophthalmopathy or orbitopathy, is an autoimmune disorder that causes inflammation in the orbital and retroocular tissues. It generally occurs as a manifestation of Graves’ disease, a condition in which the immune system attacks the thyroid gland, commonly affecting the eyes and skin. Although TED is usually found in Graves’ hyperthyroidism patients, some patients may have autoimmune euthyroid or hypothyroid thyroiditis. TED is mostly a mild, non-progressive, and self-limiting disease; however, in rare cases it can progress to vision loss. The negative impact of TED on the social and psychological well-being of individuals is an established consequence of the disease.
Thyroid eye disease (TED), also called Graves’ ophthalmopathy or orbitopathy, is an autoimmune disorder that causes inflammation in the orbital and retroocular tissues. It generally occurs as a manifestation of Graves’ disease, a condition in which the immune system attacks the thyroid gland, commonly affecting the eyes and skin. Although TED is usually found in Graves’ hyperthyroidism patients, some patients may have autoimmune euthyroid or hypothyroid thyroiditis. TED is mostly a mild, non-progressive, and self-limiting disease; however, in rare cases it can progress to vision loss. The negative impact of TED on the social and psychological well-being of individuals is an established consequence of the disease.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Definition
8 Patient segmentation
10 Symptoms
10 Risk factors
11 Diagnosis
12 TREATMENT
12 Medical treatment
12 Orbital radiotherapy
12 Surgical treatment
14 EPIDEMIOLOGY
14 Thyroid eye disease occurrence in thyroid disorders
14 Incidence methodology
17 MARKETED DRUGS
19 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 IMVT-1401 for Thyroid Eye Disease (March 30, 2020)
25 Tepezza for Thyroid Eye Disease (December 13, 2019)
26 Tepezza for Thyroid Eye Disease (December 11, 2019)
29 KEY UPCOMING EVENTS
30 KEY REGULATORY EVENTS
30 Horizon Sees Blockbuster Future For Tepezza After US Approval
31 PROBABILITY OF SUCCESS
32 LICENSING AND ASSET ACQUISITION DEALS
32 MiRagen Acquires Viridian In All-Stock Deal
33 REVENUE OPPORTUNITY
34 CLINICAL TRIAL LANDSCAPE
35 Sponsors by status
35 Sponsors by phase
36 Recent events
38 BIBLIOGRAPHY
38 Prescription information
39 APPENDIX
LIST OF FIGURES
16 Figure 1: Trends in incident cases of thyroid eye disease, 2020–29
19 Figure 2: Overview of pipeline drugs for thyroid eye disease in the US
19 Figure 3: Pipeline drugs for thyroid eye disease, by company
19 Figure 4: Pipeline drugs for thyroid eye disease, by drug type
20 Figure 5: Pipeline drugs for thyroid eye disease, by classification
25 Figure 6: IMVT-1401 for Thyroid Eye Disease (March 30, 2020): Phase IIa – ASCEND-GO 1
29 Figure 7: Key upcoming events in thyroid eye disease
31 Figure 8: Probability of success in the ophthalmology-other pipeline
34 Figure 9: Clinical trials in thyroid eye disease
34 Figure 10: Top 10 drugs for clinical trials in thyroid eye disease
35 Figure 11: Top 10 companies for clinical trials in thyroid eye disease
35 Figure 12: Thyroid eye disease trials status
36 Figure 13: Thyroid eye disease trials sponsors, by phase
LIST OF TABLES
14 Table 1: Prevalence of thyroid eye disease in Graves’ disease
15 Table 2: Incident cases of thyroid eye disease, 2020–29
18 Table 3: Marketed drugs for thyroid eye disease
21 Table 4: Pipeline drugs for thyroid eye disease in the US
23 Table 5: IMVT-1401 for Thyroid Eye Disease (March 30, 2020)
26 Table 6: Tepezza for Thyroid Eye Disease (December 13, 2019)
27 Table 7: Tepezza for Thyroid Eye Disease (December 11, 2019)
33 Table 8: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!